Archives: Speakers

Vij Senthilnathan is currently working at PTC Therapeutics, a US pharmaceutical company as Associate Director. She is a PTC leader in clinical operations working on the small molecule therapy PTC743 (vatiquinone), now in a Phase 3 global clinical trial for patients with mitochondrial disease and associated refractory epilepsy. Her involvement in rare diseases has been since 2014 starting with her role in clinical operations at BioElectron Technology Corporation (previously known as Edison Pharmaceuticals) where her responsibilities included running global clinical trials for Leigh Syndrome, Pearson Syndrome, Friedreich Ataxia, Amyotrophic lateral sclerosis (ALS), Parkinson Disease and Rett Syndrome. As a global lead and point of contact for clinical operations and strategy, she ensures effective execution of the clinical studies, strategies and mitigation plan for key regulatory submissions keeping patients first. She has been a strong advocate for patient’s voice and believes that patient advocates are an integral part of drug development process from start to finish. She works closely with different patient advocacy groups to understand their perspective for a clinical trial and ensures that the patients get asked the question they wish others would ask.

She holds a master’s degree in Molecular Medicine from University of Sheffield, UK and Bachelor’s of Technology in Biotechnology from India. She currently lives in San Francisco Bay Area, California. Her work: https://www.ptcbio.com/2021/02/08/working-to-treat-mitochondrial-epilepsy-one-seizure-at-a-time/